Search results :

Ipratropium bromide

More information: STITCH, PubChem (stereo-specific compound: 1) and possibly Wikipedia

ATC Codes: R01AX03, R03BB01

Side effects

Options: Hide MedDRA Preferred Terms ,   display all 30 labels

MedDRA Preferred Term Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Chronic obstructive pulmonary disease COPD exacerbation 8% - 23% 13% x x
Chronic obstructive pulmonary disease postmarketing x x
Bronchitis Bronchitis 2.9% - 24.5% 6% x x x x x x x x x x
Dysgeusia Bad taste 5.1% - 16% x
Dysgeusia 1.2% - 3.7% x x x x x x x x x x x
Taste bitter x x
Upper respiratory tract infection Upper respiratory tract infection 1.4% - 34% 16% x x x x x x x x x x x x x x x
Dyspnoea Dyspnoea 1.8% - 13.2% 4% x x x x x x x x x x
Urinary tract infection Urinary tract infection 2% - 10% 1% x x x x x x x x x
Flatulence Flatulence common x x
Cough Cough postmarketing — 0% - 8% 6% x x x x x x x x x x x x x x x x x x x x
Epistaxis Epistaxis 0.3% - 9% x x x x x x x
Nasal mucus blood tinged x x
Infection Infection 1.4% - 9.8% x
Headache Headache common, 0% - 9.8% 8% x x x x x x x x x x x x x x x x x x x x
Pharyngitis Pharyngitis 0% - 8.1% x x x x x x x x x x x x x x x
Influenza like illness Influenza-like symptoms 0.5% - 8% 2% x x x x x x x x x
Tremor Tremor 0.9% - 31.9% x x x x x x x
Pain Pain postmarketing, 0.9% - 4.1% x x x x x x x x x x x x x x x
Sinusitis Sinusitis postmarketing, 1% - 14% 3% x x x x x x x x x x x x x
Nasal dryness Nasal dryness 0% - 5.1% x x x x x x x
Back pain Back pain 1.9% - 7% 2% x x x x x x x x x
Rhinitis Rhinitis 2% - 6% 4% x x x x x x x x x x x x x
Bronchospasm Bronchospasm postmarketing — 2.3% - 5.4% x x x x x x x x
Bronchospasm aggravated 0.7% - 1% x
Bronchoconstriction x
Dizziness Dizziness common, 0% - 3.9% 2% x x x x x x x x x x x x x x x x x x x x
Nausea Nausea postmarketing — 0% - 4.1% 2% x x x x x x x x x x x x x x x x x x
Chest pain Chest pain 0.7% - 4.2% x x x x x x x x
Dry mouth Dry mouth common, 0% - 28.1% 2% x x x x x x x x x x x x x x x x x x x
Nervousness Nervousness 0.5% - 4.7% x x x x x x x
Tension Nervousness 0.5% - 4.7% x x x x x x x
Hypertension Hypertension 0.9% - 1.9% x x x x x x
Hypertension worsened 0.9% - 1.9% x x x x x
Sputum increased Sputum increased 1.4% - 3.4% x x x x
Increased bronchial secretion Sputum increased 1.4% - 3.4% x x x x
Nasal discomfort Nasal irritation 0% - 2% x x x x
Nasal discomfort postmarketing x x x
Nasal burning x x x x x
Nasal itching x x
Dyspepsia Dyspepsia common, 0% - 5% 1% x x x x x x
Arthritis Arthritis 0.5% - 1.4% x x x x x x
Constipation Constipation postmarketing — 0% - 1.4% x x x x x x x x x x x x x x x x x
Hyperhidrosis Sweating 0.9% x
Insomnia Insomnia 0.2% - 1.9% x x x x x x x
Visual impairment Abnormal vision 0.5% - 1.2% x
Disorder sight x
Palpitations Palpitations postmarketing — 0.5% - 2.1% x x x x x x x x x x x x x x x x x x
Dysuria Dysuria 0.2% - 1% x
Pollakiuria Pollakiuria 0.2% - 1% x
Dysphonia Dysphonia 0.2% - 1% x x
Hoarseness x x x x x x
Flushing Flushing 0% - 1.1% x
Vomiting Vomiting postmarketing — 2.1% x x x x x x x x x x
Eye pain Eye pain postmarketing — 0.9% x x x x x x x x x x x x x x x
Dry throat Dry throat uncommon x x x x
Vision blurred Vision blurred uncommon x x x x x x x x x x
Diarrhoea Diarrhoea postmarketing — 0.5% - 1.8% x x x x x x x x x x x
Hypoaesthesia Numbness in leg 0% - 1% x
Hypoaesthesia x
Nasal congestion Nasal congestion 0% - 1.1% x x x x
Nasal oedema x x
Anaphylactic shock Anaphylactic shock postmarketing, uncommon x x x x x x x x x x x x x x x x x
Angioedema Angioedema postmarketing, uncommon x x x x x x x x x x x x x x x x x x
Asthma Asthma postmarketing x
Atrial fibrillation Atrial fibrillation postmarketing, rare x x x x x x x
Corneal oedema Corneal oedema postmarketing, uncommon x x x x x x
Oedema Oedema postmarketing x x x
Dermatitis Rash postmarketing, uncommon x x x x x x x x x x x x x x x x x x x
Rash Rash postmarketing, uncommon x x x x x x x x x x x x x x x x x x x
Glaucoma Glaucoma postmarketing, uncommon x x
Glaucoma both eyes x x
Angle closure glaucoma Angle closure glaucoma postmarketing x x x x x x x x x x x x
Acute angle-closure glaucoma x x
Acute glaucoma x
Hypersensitivity Hypersensitivity postmarketing, uncommon x x x x
Intestinal obstruction Intestinal obstruction postmarketing x x x x
Laryngospasm Laryngospasm postmarketing, uncommon x x x x x x x x x x x x x x x x x x
Bronchial hyperreactivity Chronic obstructive pulmonary disease postmarketing x x
Mydriasis Mydriasis postmarketing, uncommon x x x x x x x x x x x
Pruritus Pruritus postmarketing, uncommon x x x x x x x x
Stomatitis Stomatitis postmarketing, uncommon x x x x x x
Tachycardia Tachycardia postmarketing, rare x x x x x x x x x x x x x x x x x x
Supraventricular tachycardia Supraventricular tachycardia postmarketing, uncommon x x x x x x x x x
Urticaria Urticaria postmarketing, rare x x x x x x x x x x x x x
Generalized urticaria postmarketing x x x x
Wheezing Wheezing postmarketing x x x
Urinary retention Urinary retention postmarketing — 1.4% x x x x x x x x x x x x x x x x x
Accommodation disorder Accommodation disorder postmarketing, rare x x x x x x
Intraocular pressure increased Intraocular pressure increased postmarketing, uncommon x x x x x x x x x
Eye irritation Eye irritation postmarketing x x x x
Pharyngeal oedema Pharyngeal oedema postmarketing, uncommon x x x x x x
Oedema mouth Oedema mouth postmarketing, uncommon x x x x x x
Bronchospasm paradoxical Bronchospasm paradoxical postmarketing, uncommon x x x x x
Halo vision Halo vision postmarketing, uncommon x x x x x x
Abdominal discomfort Distress gastrointestinal postmarketing x x x x
Throat irritation Throat irritation postmarketing, common x x x x x x x
Gastrointestinal motility disorder Gastrointestinal motility disorder postmarketing, common x x x x x
Conjunctival hyperaemia Conjunctival hyperaemia postmarketing, uncommon x x x x x
Abdominal pain Abdominal pain x
Gastrointestinal pain Abdominal pain x
Congenital anomaly Congenital anomaly x
Developmental delay Congenital anomaly x
Breast feeding Breast feeding
Cardiovascular disorder Cardiovascular disorder x x x x x x
Conjunctivitis Conjunctivitis x x x x x x x
Dysphagia Dysphagia
Eye disorder Eye disorder x x x
Asthenia Fatigue x x
Fatigue Fatigue x x
Gastrointestinal disorder Gastrointestinal disorder x x x
Cardiac disorder Cardiac disorder x x x
Haemorrhage Haemorrhage x x x x
Haemoglobin Haemorrhage x x x x
Type I hypersensitivity Type I hypersensitivity x x
Hypotension Hypotension x x
Immune system disorder Immune system disorder x x x
Inflammation Inflammation
Lung disorder Lung disorder
Mediastinal disorder Mediastinal disorder x x x
Nasal polyps Nasal polyps x x
Nervous system disorder Nervous system disorder x x x
Paraesthesia Paraesthesia x
Neuropathy peripheral Neuropathy peripheral x x x
Pregnancy Pregnancy x
Salivary hypersecretion Salivary hypersecretion x
Status asthmaticus Status asthmaticus x
Swelling Swelling
Thirst Thirst x x x
Tinnitus Tinnitus x x x
Ulcer Ulcer x x
Urethral disorder Urinary tract disorder x x x x x x
Urinary tract disorder Urinary tract disorder x x x x x x
Tongue disorder Tongue oedema
Tongue oedema Tongue oedema
Skin disorder Unspecified disorder of skin and subcutaneous tissue x x x
Myalgia Myalgia x x
Musculoskeletal discomfort Myalgia x x
Swollen tongue Swollen tongue
Heart rate irregular Heart rate irregular
Prostatomegaly Prostatomegaly
Nasal oedema Nasal oedema x x
Emotional distress Emotional distress
Local reaction Local reaction x
Oropharyngeal swelling Oropharyngeal swelling x x x
Foetal damage Foetal damage x
Influenza Flu symptoms x
Somnolence Somnolence x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

IPRATROPIUM

Side effects:22
Source:FDA Structured Product Label

IPRATROPIUM

Side effects:22
Source:FDA Structured Product Label

IPRATROPIUM BROMIDE

Side effects:32
Source:FDA Structured Product Label

IPRATROPIUM

Side effects:34
Source:FDA Structured Product Label

IPRATROPIUM

Side effects:34
Source:FDA Structured Product Label

IPRATROPIUM

Side effects:35
Source:FDA Structured Product Label

Ipratropium cation

Side effects:35
Source:FDA Structured Product Label

IPRATROPIUM

Side effects:36
Source:FDA Structured Product Label

IPRATROPIUM BROMIDE

Side effects:36
Source:FDA Structured Product Label

ipratropium bromide HFA / Atrovent HFA

Side effects:37
Source:FDA

IPRATROPIUM BROMIDE / ATROVENT HFA

Side effects:40
Source:Health Canada

IPRATROPIUM

Side effects:43
Source:FDA Structured Product Label

Ipratropium bromide / ATROVENT Metered Aerosol (CFC-free)

Side effects:47
Source:medicines.org.au

DESCRIPTION / ATROVENT NASAL and ATROVENT NASAL FORTE

Side effects:50
Source:medicines.org.au

IPRATROPIUM

Side effects:53
Source:FDA Structured Product Label

IPRATROPIUM

Side effects:53
Source:FDA Structured Product Label

IPRATROPIUM

Side effects:55
Source:FDA Structured Product Label

Color scheme:

standardalternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label